Related references
Note: Only part of the references are listed.Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis
Jashin J. Wu et al.
CURRENT MEDICAL RESEARCH AND OPINION (2020)
Adherence to subcutaneous anti-TNFα agents in patients with rheumatoid arthritis is largely influenced by pain and skin sensations at the injection site
Fausto Salaffi et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2020)
Mode of injection and treatment adherence: results of a survey characterizing the perspectives of health care providers and US women 18-45 years old
David L. Gandell et al.
PATIENT PREFERENCE AND ADHERENCE (2019)
Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site
Iris Usach et al.
ADVANCES IN THERAPY (2019)
Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis
David T. Rubin et al.
Journal of Managed Care & Specialty Pharmacy (2017)
Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis
Peter Nash et al.
RHEUMATOLOGY AND THERAPY (2016)
Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective
Susan C. Bolge et al.
PATIENT PREFERENCE AND ADHERENCE (2015)
Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort
James Bluett et al.
RHEUMATOLOGY (2015)
Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial
T. Heise et al.
DIABETES OBESITY & METABOLISM (2014)
Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting
Machaon Bonafede et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2013)
Etanercept and Adalimumab Treatment Patterns in Psoriatic Arthritis Patients Enrolled in a Commercial Health Plan
Benjamin Chastek et al.
ADVANCES IN THERAPY (2012)
Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study
G. Anderson et al.
JOURNAL OF NEUROLOGY (2010)
Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs
Bijan J. Borah et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Changing Patterns of Tumor Necrosis Factor Inhibitor Use in 9074 Patients with Rheumatoid Arthritis
Yusuf Yazici et al.
JOURNAL OF RHEUMATOLOGY (2009)
A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis
Amer Jaber et al.
BMC NEUROLOGY (2008)
Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis
Carlos G. Grijalva et al.
MEDICAL CARE (2007)
A meta-analysis of the association between adherence to drug therapy and mortality
Scot H. Simpson et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Pain perception after subcutaneous injections of media containing different buffers
T Laursen et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2006)
The impact of non-compliance on the cost-effectiveness of pharmaceuticals: A review of the literature
DA Hughes et al.
HEALTH ECONOMICS (2001)
Share Paper
